No causative genes or hereditary predisposition data are recorded for NKTCL in this packet. No inheritance pattern is documented.

No specific diagnostic methods or biomarkers for NKTCL are recorded in this packet beyond the disease definition and classification as a malignant neoplasm of the nasal and upper airway region.

No approved treatments or foundational therapies for NKTCL are recorded in this packet. Active clinical trial investigation across drug therapy, biologic, procedural, and other intervention categories is ongoing, with both academic and industry sponsorship represented.

According to the disease definition in this packet, advanced disease stages of NKTCL are associated with poor prognosis. No additional quantitative prognosis data are provided in this packet.

Active clinical trials with specific scope for extranodal NK/T cell lymphoma include: NCT07502768 ("Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma"; Phase 1; sponsor: Rong Tao; status: recruiting; start: April 2026; completion: December 2028); NCT05700448 ("Sugemalimab or Placebo Plus PGemOx Regimen in Extranodal NK/T-Cell Lymphoma"; Phase 3; CStone Pharmaceuticals; not yet recruiting; projected start: June 2027; completion: December 2030); NCT07574528 ("Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Stage I/II Extranodal NK/T-Cell Lymphoma"; Phase 2; Sun Yat-sen University; not yet recruiting; projected start: May 2026; completion: May 2031); NCT07554482 ("Selinexor Combined With Reduced-Dose Radiotherapy for Early-Stage Extranodal NK/T-Cell Lymphoma"; Phase 2; Beijing Tongren Hospital; not yet recruiting; projected start: May 2026; completion: April 2029). The classified publication landscape encompasses 162 publications (43 reviews, 37 case reports), with biomarker and gene therapy publications documented.